BidaskClub Upgrades Lexicon Pharmaceuticals (LXRX) to “Hold”

Share on StockTwits

BidaskClub upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a sell rating to a hold rating in a research note published on Thursday.

Other analysts also recently issued research reports about the stock. Citigroup reissued a buy rating and issued a $14.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Tuesday, January 22nd. They noted that the move was a valuation call. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a hold rating to a buy rating and set a $6.50 price objective for the company in a research note on Thursday, January 24th. ValuEngine raised shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, January 25th. Finally, Wedbush set a $36.00 price objective on shares of Lexicon Pharmaceuticals and gave the stock an outperform rating in a research note on Tuesday, January 22nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $20.38.

NASDAQ LXRX traded up $0.27 during trading on Thursday, hitting $7.60. The stock had a trading volume of 6,048 shares, compared to its average volume of 870,616. The company has a market cap of $789.14 million, a P/E ratio of -5.91 and a beta of 0.70. Lexicon Pharmaceuticals has a one year low of $4.26 and a one year high of $13.97.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.12. The business had revenue of $17.10 million during the quarter, compared to the consensus estimate of $13.33 million. Lexicon Pharmaceuticals had a negative net margin of 168.23% and a negative return on equity of 1,247.65%. The firm’s quarterly revenue was down 49.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.27) earnings per share. As a group, research analysts predict that Lexicon Pharmaceuticals will post -1.28 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Lexicon Pharmaceuticals by 1.9% during the third quarter. Vanguard Group Inc. now owns 3,834,766 shares of the biopharmaceutical company’s stock valued at $40,917,000 after acquiring an additional 72,640 shares in the last quarter. Vanguard Group Inc raised its stake in shares of Lexicon Pharmaceuticals by 1.9% during the third quarter. Vanguard Group Inc now owns 3,834,766 shares of the biopharmaceutical company’s stock valued at $40,917,000 after acquiring an additional 72,640 shares in the last quarter. Clearbridge Investments LLC raised its stake in shares of Lexicon Pharmaceuticals by 974,268.4% during the third quarter. Clearbridge Investments LLC now owns 1,295,910 shares of the biopharmaceutical company’s stock valued at $13,827,000 after acquiring an additional 1,295,777 shares in the last quarter. Northern Trust Corp raised its stake in shares of Lexicon Pharmaceuticals by 2.1% during the second quarter. Northern Trust Corp now owns 584,393 shares of the biopharmaceutical company’s stock valued at $7,013,000 after acquiring an additional 12,289 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Lexicon Pharmaceuticals by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 565,085 shares of the biopharmaceutical company’s stock valued at $3,752,000 after acquiring an additional 13,664 shares in the last quarter. 99.34% of the stock is owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Read More: What is a blue-chip stock?

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.